Brenda Smith
Family · West Monroe, LANPI 1730493966
Payments from drug & device makers
Across 124 payments — averaging $13.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$641
- Merck$164
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$133
- AstraZeneca$128
- Lexicon Pharmaceuticals, Inc.$123
- Bayer$92
- plus $396 from 11 others
What the payments were for
- Food & beverage$1,676100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 52 | $641 |
| Merck | 8 | $164 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $133 |
| AstraZeneca | 8 | $128 |
| Lexicon Pharmaceuticals, Inc. | 6 | $123 |
| Bayer | 5 | $92 |
| Boehringer Ingelheim | 4 | $68 |
| Amarin Pharma, Inc. | 3 | $61 |
| Amgen | 3 | $60 |
| Pfizer | 3 | $48 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Itamar Medical Inc | 1 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $24 |
| Boston Scientific | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $14 |
How this compares
$1,676 in reported general payments places this provider in the 70th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 217 | $173,081 |
| EntrestoSacubitril/Valsartan | 188 | $153,916 |
| FarxigaDapagliflozin Propanediol | 81 | $55,270 |
| XareltoRivaroxaban | 32 | $21,431 |
| Repatha SureclickEvolocumab | 11 | $10,418 |
| Ranolazine ErRanolazine | 66 | $3,843 |
| Nitroglycerin PatchNitroglycerin | 92 | $3,579 |
| Enoxaparin Sodium | 21 | $3,005 |
| Hydralazine Hcl | 269 | $2,614 |
| Nitroglycerin | 261 | $2,499 |
| Metoprolol Succinate | 210 | $2,465 |
| Atorvastatin Calcium | 258 | $2,255 |
| ClopidogrelClopidogrel Bisulfate | 153 | $1,863 |
| Losartan Potassium | 184 | $1,507 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 136 | $1,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $173,081217 claims |
| NovartisEntresto | $641 | $153,916188 claims |
| AstraZenecaFarxiga | $128 | $55,27081 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,610 family providers in Louisiana.
Other family in West Monroe
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.